BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 18977540)

  • 1. Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction.
    Yamazaki J; Baba K; Goto-Koshino Y; Setoguchi-Mukai A; Fujino Y; Ohno K; Tsujimoto H
    Vet Immunol Immunopathol; 2008 Dec; 126(3-4):321-31. PubMed ID: 18977540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Detection of minimal residual diseases in B-cell tumors using PCR specific for the immunoglobulin heavy chain gene].
    Matolcsy A; Borbényi Z; Demeter J; Egyed M; Fekete S; Földi J; Gergely L; Kajtár P; Kelényi G; Kiss A; László T; Lehoczky D; Losonczy H; Nagy M; Pál K; Pálóczy K; Radványi G; Semsei I; Varga G; Udvardy M
    Orv Hetil; 2000 Jun; 141(25):1403-6. PubMed ID: 10934884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic organization of the T-cell receptor gamma gene and PCR detection of its clonal rearrangement in canine T-cell lymphoma/leukemia.
    Yagihara H; Tamura K; Isotani M; Ono K; Washizu T; Bonkobara M
    Vet Immunol Immunopathol; 2007 Feb; 115(3-4):375-82. PubMed ID: 17166595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative nested reverse transcriptase PCR vs. real-time PCR for measuring AML1/ETO (MTG8) transcripts.
    Takenokuchi M; Yasuda C; Takeuchi K; Nakamachi Y; Mukai M; Kondo S; Kumagai S; Saigo K; Murayama T; Koizumi T; Tatsumi E
    Clin Lab Haematol; 2004 Apr; 26(2):107-14. PubMed ID: 15053804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
    Chan DW; Liang R; Kwong YL; Chan V
    Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology.
    Nakao M; Janssen JW; Flohr T; Bartram CR
    Cancer Res; 2000 Jun; 60(12):3281-9. PubMed ID: 10866322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal residual disease in canine lymphoma: An objective marker to assess tumour cell burden in remission.
    Sato M; Yamazaki J; Goto-Koshino Y; Setoguchi A; Takahashi M; Baba K; Fujino Y; Ohno K; Tsujimoto H
    Vet J; 2016 Sep; 215():38-42. PubMed ID: 27339366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined polymerase chain reaction methods to detect c-myc/IgH rearrangement in childhood Burkitt's lymphoma for minimal residual disease analysis.
    Busch K; Borkhardt A; Wössmann W; Reiter A; Harbott J
    Haematologica; 2004 Jul; 89(7):818-25. PubMed ID: 15257933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increase in minimal residual disease in peripheral blood before clinical relapse in dogs with lymphoma that achieved complete remission after chemotherapy.
    Sato M; Yamazaki J; Goto-Koshino Y; Takahashi M; Fujino Y; Ohno K; Tsujimoto H
    J Vet Intern Med; 2011; 25(2):292-6. PubMed ID: 21314721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of minimal residual disease (MRD) after multidrug chemotherapy and its correlation to outcome in dogs with lymphoma: a proof-of-concept pilot study.
    Yamazaki J; Takahashi M; Setoguchi A; Fujino Y; Ohno K; Tsujimoto H
    J Vet Intern Med; 2010; 24(4):897-903. PubMed ID: 20492493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma.
    Fenk R; Ak M; Kobbe G; Steidl U; Arnold C; Korthals M; Hünerlitürkoglu A; Rohr UP; Kliszewski S; Bernhardt A; Haas R; Kronenwett R
    Haematologica; 2004 May; 89(5):557-66. PubMed ID: 15136219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
    Pott C; Brüggemann M; Ritgen M; van der Velden VH; van Dongen JJ; Kneba M
    Methods Mol Biol; 2013; 971():175-200. PubMed ID: 23296964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma.
    Novella E; Giaretta I; Elice F; Madeo D; Piccin A; Castaman G; Rodeghiero F
    Haematologica; 2002 Nov; 87(11):1157-64. PubMed ID: 12414345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective monitoring of minimal residual disease using hairpin-shaped clone specific primers in B-cell lymphoma affected dogs.
    Gentilini F; Turba ME; Forni M
    Vet Immunol Immunopathol; 2013 Jun; 153(3-4):279-88. PubMed ID: 23602204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant DNA methylation of the p57KIP2 gene is a sensitive biomarker for detecting minimal residual disease in diffuse large B cell lymphoma.
    Hagiwara K; Li Y; Kinoshita T; Kunishma S; Ohashi H; Hotta T; Nagai H
    Leuk Res; 2010 Jan; 34(1):50-4. PubMed ID: 19616848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease detection by flow cytometry and PARR in lymph node, peripheral blood and bone marrow, following treatment of dogs with diffuse large B-cell lymphoma.
    Aresu L; Aricò A; Ferraresso S; Martini V; Comazzi S; Riondato F; Giantin M; Dacasto M; Guadagnin E; Frayssinet P; Rouquet N; Drigo M; Marconato L
    Vet J; 2014 May; 200(2):318-24. PubMed ID: 24698669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of the polymerase chain reaction assay based on the canine genome database for detection of monoclonality in B cell lymphoma.
    Tamura K; Yagihara H; Isotani M; Ono K; Washizu T; Bonkobara M
    Vet Immunol Immunopathol; 2006 Mar; 110(1-2):163-7. PubMed ID: 16325266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
    Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
    Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
    Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
    J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-time quantitative PCR using hairpin-shaped clone-specific primers for minimal residual disease assessment in an animal model of human non-Hodgkin lymphoma.
    Gentilini F; Turba ME; Calzolari C; Cinotti S; Forni M; Zannoni A
    Mol Cell Probes; 2010 Feb; 24(1):6-14. PubMed ID: 19651205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.